Results 11 to 20 of about 4,816,902 (277)
Novel psychoactive substances of interest for psychiatry [PDF]
World Psychiatry, 2015 Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribed medications, psychoactive plants/herbs, and a large series of performance and ...
Fabrizio, Schifano +3 more
core +5 more sources
Pharmacology of novel psychoactive substances [PDF]
, 2016 This PhD work consists of an in vitro and in vivo part. In the in vivo part, we investigated the role of dopamine in the acute clinical effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects. The role of dopamine in the addictive effects of drug of abuse is well established, but whether it contributes to the acute ...
Rickli, Anna
openaire +3 more sources
Novel psychoactive substance [PDF]
Clinical Medicine, 2021 Editor – We read with interest the article entitled ‘Acute neurological consequences of novel psychoactive substance use: a retrospective review in a large UK hospital’ by Tanti et al .[1][1] The team have effectively highlighted the high rates of psychiatric comorbidity, unemployment,
Mark, Pucci +2 more
openaire +2 more sources
Critically discussing the trends surrounding novel psychoactive substances. [PDF]
Novel psychoactive substances (NPS), previously known as ‘legal highs’, have been common in the UK for many years (EMCDDA, 2018). The aim of this research work was to combine spectroscopic analysis with review of literature to assess the trends arising ...
Masters, Jake
core +8 more sources
The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review
Brain Sciences, 2021 Introduction: Cognitive enhancers (CEs), also known as “smart drugs”, “study aids” or “nootropics” are a cause of concern. Recent research studies investigated the use of CEs being taken as study aids by university students.
Safia Sharif +3 more
doaj +1 more source
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2017 There has been a significant increase in the number of new intoxicants on the illegal drugs market globally, also in Norway. The substances are given the name NPS: Novel Psychoactive Substances, and are mainly sold over the Internet. Uncertain dosage of potent substances entails a risk of accidental overdose, and therefore serious intoxication and ...
M.T. Zanda, L. Fattore
+6 more sources
Brain Sciences, 2023 The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and others) now promises effective, non-invasive treatment of obesity for individuals with and without diabetes.
Davide Arillotta +7 more
doaj +1 more source
Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach
Frontiers in Psychiatry, 2021 COVID-19-related disruptions of people and goods' circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of
Valeria Catalani +8 more
doaj +1 more source
COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis
Brain Sciences, 2021 The restrictive measures adopted during the COVID-19 pandemic modified some previously consolidated drug use patterns. A focus on social networks allowed drug users to discuss, share opinions and provide advice during a worldwide emergency context.
Davide Arillotta +4 more
doaj +1 more source
Pharmaceuticals, 2021 Designer benzodiazepines (DBZDs) represent a serious health concern and are increasingly reported in polydrug consumption-related fatalities. When new DBZDs are identified, very limited information is available on their pharmacodynamics.
Valeria Catalani +6 more
doaj +1 more source